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BAckground: Invasive Aspergillosis(IA) is a serious invasive fungal 
infection(IFI), usually affecting immunocomprised patients. In the Netherlands, 
voriconazole(VOR) is the recommended primary targeted antifungal agent and is 
used for the vast majority of IA patients. After unsuccessful first line treatment 
with VOR, Caspofungin(CASP) and liposomal amphotericin B(L-AMB) are two most 
commonly used agents. In a previously published study, CASP was dominant over 
L-AMB, as a targeted salvage antifungal therapy option after VOR for IA treatment 
in the Netherlands. However, trial data used as input might not reflect the real 
world effectiveness of treatment strategies. oBjectives: The objective of this 
study is to conduct a cost-effectiveness analysis of the most common targeted 
antifungal treatment sequences for IA in the Netherlands, using real-world data 
from a national registry. Methods: A previously developed decision analytical 
model was adapted to carry out the cost-effectiveness analysis that compares 
L-AMB vs. CASP as a 2nd line treatment strategy after unsuccessful treatment 
with VOR. Findings from the analysis of the national patient registry informed the 
model structure, treatment patterns, duration/dosage of treatments, events and 
their probabilities. The model estimates both survival during infectious disease 
episode as well as life years saved(LYS) after short-term survival. Extensive sensi-
tivity analyses were conducted to assess the robustness of the results. results: 
Short term survival, life expectancy and cost outcomes for using L-AMB and CASP 
in the 2ndline seem to be similar, after an unsuccessful primary therapy with 
VOR. There is a slight benefit in terms of LYS and costs for L-AMB. The analysis 
results are sensitive to statistical uncertainty due to the low number of patients 
in the registry. conclusions: An updated analysis after more data is collected 
would strengthen reliability/validity of the analysis, and would make it feasible 
to apply statistical matching Methods to adjust for possible confounding by treat-
ment choice.
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oBjectives: Rapid advances in the development of direct-acting antivirals (DAAs) 
have shifted the challenge of treating chronic hepatitis C virus (HCV) from a medical 
challenge to a socioeconomic issue of affordability. A 12-week course of all-oral DAA 
costs approximately USD 84,000. To date, no study has been conducted to determine 
the cost-effectiveness of various DAAs within an Asian context. Methods: We per-
formed a Markov model to simulate a cohort of 50 year-old HCV infected patients 
through 14 treatment strategies over life-time period. Treatment effects including 
sustained virological response and adverse events including anemia, neutropenia and 
thrombocytopenia were derived from published trials. Costs were obtained from a ter-
tiary hospital in Singapore. Subset analysis was conducted to incorporate the implica-
tion of retreatment that reflected real-life situation. results: Using response-guided 
boceprevir (BOC/RGT, least costly treatment) as a base-case, peginterferon/ribavirin, 
48-week boceprevir and genotype-guided therapies were dominated by BOC/RGT as 
they were more costly and less effective. Using the Singapore gross domestic product 
of USD 52,500 as the threshold, 12 weeks of Viekira Pak (ombitasvir/paritaprevir/rito-
navir/dasabuvir) and sofosbuvir/ledipasvir were cost-effective and marginally cost-
effective respectively. Other all-oral DAAs were either dominated by Viekira Pak or 
sofosbuvir/ledipasvir. Roadmap therapy using rapid virologic-response to guide use of 
boceprevir and sofosbuvir was associated with favourable incremental cost per qual-
ity-adjusted life year gained (USD 16,130). BOC/RGT and roadmap therapy remained 
as cost-effective treatment options by incorporating retreatment. conclusions: 
HCV management can be optimised by adopting value-based treatment algorithm 
such as roadmap therapy that offers best value for money.
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oBjectives: Streptococcus pneumonia causes a number of clinical conditions, 
including pneumonia, meningitis, bacteremia, sepsis, and acute otitis media (AOM). 
The objective of this study is to estimate the potential effectiveness and cost-effec-
tiveness of vaccinating infants with the pneumococcal non-typeable Haemophilus 
influenzae Protein D conjugate vaccine (PHiD-CV) compared to the 13-valent pneu-
mococcal conjugate vaccine (PCV-13) in Croatia. These vaccines are currently avail-
able only for risk groups and on private market with a limited uptake, representing 
less than 10% of annual birth cohort. Methods: A Markov cohort model with a 
starting birth cohort of 39,939 infants and a 100-year time horizon was used to 
project the impact of vaccination on the incidence of pneumococcal diseases. In 
the model, individuals move between mutually-exclusive health states and direct 
treatment costs and quality-adjusted life years (QALYs) are aggregated and dis-
counted (3%) in monthly cycles. Vaccine regimen was 2+1 schedule with doses given 
at 2, 4, and 13 months for both vaccines. results: Under our model assumptions 
and assuming both vaccines have the same price, PHiD-CV is predicted to save 
both 13 QALYs and € 138,564 compared to PCV-13 (dominant intervention). Both 
vaccines would prevent about the same numbers of IPD and pneumonia whereas 
PHiD-CV would save more GP visits and clinical interventions related to AOM. If the 
model further accounts for the difference in list price between the two vaccines, 
then vaccinating Croatian infants with PHiD-CV would save a total of € 1,192,753 
compared to PCV-13. Parameters infuencing the most model results are related to 
AOM management (e.g. percentage reduction in myringotomy and disutility for 
outpatient AOM). conclusions: Our results show PHiD-CV dominates PCV-13 in 
most scenarios due to incremental benefits in AOM. Vaccinating with PHiD-CV in 
Croatia could save a substantial health care budget.
of male patients. Total costs (direct medical cost, indirect cost) and quality-adjusted 
life-year (QALY) loss for post-biopsy infection care were outcomes of analysis. Model 
inputs were retrieved from clinical studies published in literature. Sensitivity analysis 
was conducted to examine robustness of model results. results: The base-case 
analysis found rectal culture-guided strategy to be less costly (expected cost HKD1,268 
versus HKD1,633) (USD1= HKD7.8) with lower QALY loss (0.00055 QALY vs 0.00084 
QALY) when compared to empirical strategy. Sensitivity analysis showed that the 
total cost of rectal culture-guided arm would become higher than the empirical arm 
if the effectiveness of rectal culture-guided strategy in reducing post-biopsy infec-
tion was less than 12.07%, or if post-biopsy infection rate of empirical strategy was 
lower than 3.18%. In 10,000 Monte Carlo simulations, rectal culture-guided arm was 
the preferred option in 98.67% of cases with mean total cost saving of HKD449 per 
patient (95%CI HKD443–455; p < 0.001) and lower mean QALY loss of 0.000335 QALYs 
per patient (95%CI 0.000332–0.000338 QALYs; p < 0.001). conclusions: Comparing 
with empirical antibiotic prophylaxis, the use of rectal swab culture to guide the 
choice of antibiotic prophylaxis seems to be a cost-saving and effective intervention 
in men undergoing TRUSBx in Hong Kong.
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oBjectives: Chronic hepatitis C virus (HCV) is a considerable public health concern 
due to its significant impact on morbidity, mortality and healthcare costs. Treatment 
of HCV genotype 1 (GT1)-infected patients with ombitasvir/paritaprevir/ritonavir and 
dasabuvir with or without ribavirin (OBV/PTV/r/DSV±R) demonstrated significantly 
high sustained viral response (SVR) rates and negligible adverse events in clinical 
studies. This study evaluated the cost per SVR for OBV/PTV/r/DSV±R compared to 
sofosbuvir in combination with daclatasvir (SOF+DCV) or simeprevir (SOF+SIM) in 
HCV treatment-naïve patients with GT1 for The Netherlands. Methods: An eco-
nomic evaluation comparing OBV/PTV/r/DSV±R to SOF+DCV or SOF+SIM in terms of 
costs per SVR was performed from the Dutch societal perspective. A Markov model 
with a lifetime time horizon was developed based on previous published models in 
HCV. Transition probabilities, resource use and costs for reference year 2014 were 
derived from the literature, publically available sources and expert opinion. SVR rates 
for all therapies were derived from published literature. Baseline characteristics (e.g., 
age, fibrosis distribution) were based on the OBV/PTV/r/DSV±R trials. results: In 
treatment-naïve HCV GT1 patients, the overall trial SVR rate for OBV/PTV/r/DSV±R 
was 97% (688/708), 98% (124/126) for SOF+DCV and 89% (17/19) for SOF+SIM. Total 
costs were lower for OBV/PTV/r/DSV±R (€ 55,864) compared to SOF+DCV (€ 83,679) 
and SOF+SIM (€ 81,746). Total costs per SVR were also lower for OBV/PTV/r/DSV±R 
(€ 57,592) compared to SOF+DCV (€ 85,387) and SOF+SIM (€ 91,849). Treatment with 
OBV/PTV/r/DSV±R resulted in a cost-savings of € 27,795 and € 34,257 per responding 
patient compared to SOF+DCV and SOF+SIM, respectively. conclusions: Total costs 
per successfully treated treatment-naïve HCV GT1 patient with OBV/PTV/r/DSV±R 
are lower compared to sofosbuvir in combination daclatasvir or simeprevir for the 
Dutch society. Treatment with OBV/PTV/r/DSV±R would lead to cost-savings and thus 
improve the overall budget impact of HCV in the Netherlands.
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oBjectives: To assess cost-effectiveness of voriconazole compared to other medi-
cations recommended in Russia for treatment of invasive aspergillosis (IA) in 
adults. Methods: We developed «decision tree» model, comparing 3 alternative 
first-line therapies in IA: 1) voriconazole, 2), caspofungin, or 3) amphotericin B lipid 
complex (LC). Efficacy was assessed as the probability of patient survival within 14 
weeks of starting treatment. Transition probabilities were calculated on the basis 
of data derived from published clinical research on IA treatment. Costs were cal-
culated as the sum of drugs cost (based on prices in public procurement) and cost 
of prolonged stay in hospital due to serious adverse events (based on the average 
bed-day cost in public health care). In additional model, conventional ampho-
tericin B instead of its LC was administered. Probabilistic sensitivity analysis was 
performed for both models. Costs were converted to EUROs using the average 
weighted exchange rate in 2014 (1€ = 50.815RUR). results: In the base case model 
voriconazole was a dominant strategy for IA treatment (per patient survival 0.742 
and cost € 10,556) in comparison with caspofungin (0.652 and € 17,272, respectively) 
and amphotericin B lipid complex (0.719 and € 34,441). Probabilistic sensitivity 
analysis (1000 simulations) showed the robustness of results. In additional model 
the willingness-to-pay threshold, at which voriconazole had more chances to 
be considered cost-effective in comparison with conventional amphotericine B 
varied from € 984 to € 21,647 per life saved, depending on the choice of second 
line therapy. conclusions: Voriconazole was shown to be either dominant or 
cost-effective strategy for treatment of IA in comparison with other therapies 
recommended in Russian practice.
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with 13,961,659KRW (1,100 KRW= 1 USD) additional cost spent compared to a patient 
in SR alone with an incremental cost-utility ratio (ICUR) of 11,638,656KRW/QALY. 
Bedaquiline plus SR had a 80% probability of being cost-effective at a willingness 
to pay threshold of 26,000,000KRW when compared with SR alone. conclusions: 
The results of this study indicate that bedaquiline is a cost-effective option for the 
treatment of MDR (including XDR-TB patients) in the Korean settings when com-
pared to standard treatment alone.
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oBjectives: The main objetive was to evaluate the cost reduction by introduction 
of equivalent therapeutic program after the accord in the Central Pharmaceutical 
Commission in Extremadura. Methods: Retrospective observational study 
between March 2013 and March 2014. We agree that micafungin was the pref-
erential echinocandin for the same indication. Caspofungin was restricted for 
empiric treatment of fungal infection in patients with fever and neutropenia and 
Anidulafungin was used in patients with hepatic dysfunction. To quantify the 
avoided costs we extracted consumption data and costs of antifungals from the 
Pharmacy Department Multibase v.3. Program (Dominion) and compared them with 
the same period the previous year. results: Regarding avoided costs for the period 
of the study, echinocandins costs were reduced by 353.965 euros, a 24,35 % less than 
previous year. In the first period, the echinocandin most used was caspofungin 
(51,23%) because the prescription wasn´t restricted and the physician could use 
anyone. In the second period, we observed a 31,63% increase in use in micafungin, 
the echinocandin that we evaluated the most efficient in our protocol. The use of 
caspofungin and anidulafungin decreased a 11,92% and 19,71% respectively. These 
use involved a decrease in cost too, 255.836 and 254.896 euros less about anidu-
lafungin and caspofungin use respectively. These results are consistent with the 
recommendations contained in our program (first line use of micafungin in nonim-
munosuppressed patients with candida infection). conclusions: Our therapeutic 
program compliance was good at our hospitals, resulting in a significant decrease 
in echinocandins expenses. Maybe, the implementation of these type of programs 
in the management of high-cost drugs resulted in significant cost reductions and 
therefore in a more rational use of healthcare budgets.
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oBjectives: The duration of current standard dual and triple therapies for HCV-G1 
is determined by assessment of early viral kinetics. We conducted a cost analysis 
to determine the main cost of treatment for a patient with HCV-G1 with dual or 
triple therapy, where the duration of the therapy (24 or 48 weeks) is guided by HCV-
RNA assay. Methods: HCV-RNA was assessed by two widely used real-time PCR-
based assays, Cobas Ampliprep/Cobas TaqMan (CAP-CTM) and Real-Time HCV (ART). 
Considering the dual therapy (PegINFα -2b and RBV) at week 12 of treatment, 16% of 
patients (27/169) were eligible to receive a shorter duration of therapy (24 weeks) 
according to CAP-CTM and 9% (16/169) to ART: 26 patients achieved SVR with CAP-
CTM and 15 with ART. Considering the triple therapy (TPV, PegINFα -2a and RBV) at 
week 12 of treatment, 60% of patients (31/52) were eligible to receive a shorter dura-
tion of therapy (24 weeks) according to CAP-CTM and 25% (13/52) to ART: 30 patients 
achieved SVR with CAP-CTM and 13 with ART. The cost analysis was conducted 
from the perspective of the Italian National Health Service (NHS). Only drugs (TPV, 
PegINFα -2b, PegINFα -2b and RBV) and tests (CAP-CTM and ART) costs were consid-
ered. Ex-factory prices (included all discounts) and National Tariffs were considered 
to appraise drug consumptions and tests, respectively. Costs were assessed in Euros 
in 2015. results: Considering the dual therapy, the overall main treatment cost per 
patient with CAP-CTM (€ 9,743.63) was lower than with ART (€ 10,053.46). Taking into 
account the triple therapy, the overall main treatment cost per patient was lower 
with CAP-CTM (€ 31,630.69) than with ART (€ 33,463.24). conclusions: CAP-CTM 
HCV-RNA assay was cost-saving from the Italian NHS perspective compared to ART 
HCV-RNA assay in dual (-€ 309.83 cost per patient) and triple (-€ 1,832.55 cost per 
patient) HCV therapy.
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oBjectives: Adults ≥ 65 years account for most seasonal influenza-related hospitali-
zations and deaths. A recent head-to-head RCT (FIM12, NCT01427309) demonstrated 
that a high-dose influenza vaccine (HD) was 24.2% more efficacious than a standard-
dose influenza vaccine (SD) in preventing laboratory-confirmed influenza-like illness 
among 31,989 adults ≥ 65 years. A cost-utility analysis (CUA) of HD vs. SD in FIM12 
participants was performed. Methods: Health-care resource utilization data col-
lected in the FIM12 study utilized resources (medications, non-routine medical visits, 
emergency room visits, and hospitalizations) were summarized across vaccine arms 
and unit costs were applied, using standard Canadian cost sources (in CAD), to each 
resource item (including vaccines; HD $31.82; SD $5.82) to estimate the mean total 
direct medical and societal costs associated with each vaccine. Health outcomes data 
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oBjectives: To evaluate the cost-effectiveness of an integrase inhibitor (INI), 
dolutegravir (DTG), in combination with abacavir(ABC)/lamivudine(3TC) in France, 
in treatment-naïve (TN) HIV adult patients. Methods: The ARAMIS microsimula-
tion Markov model, including HIV health states with and without opportunistic 
infection, evaluates costs and effects of first line options including INIs (raltegravir 
[RAL], elvitegravir/c), protease inhibitors (PI) (darunavir [DRV/r], atazanavir/r, lopi-
navir [LPV/r]), efavirenz (EFV) and rilpivirine at a life time horizon with a monthly 
cycle length. Efficacy and safety data were derived from phase III studies (SPRING 2, 
FLAMINGO and SINGLE including comparators RAL, DRV/r and EFV respectively) and 
network meta-analyses for other comparators. Treatment algorithms were based on 
French guidelines and experts opinion accounting for patient’s treatment history, 
including INI resistance status. Costs, from a collective perspective included rou-
tine HIV and opportunistic infection care, and death. results: The model showed 
DTG/ABC/3TC was more effective than all other recommended regimens: patients 
stayed longer on first line, and lived longer and healthier (incremental life years 
ranged from 0.305 to 0.71 and QALYs from 0.085 to 0.28 versus RAL and LPV/r). With 
the exception of EFV, DTG was dominant compared to all strategies, with the larg-
est cost savings for INIs (incremental costs of -€ 21,556 for RAL). The cost per QALY 
gained (ICER) for DTG compared to EFV was € 6,939 (incremental QALYs and costs 
of 0.10 and +€ 692, respectively). Deterministic sensitivity analyses (DSA) showed 
that DTG was dominant compared to INIs and PIs in all DSA. Compared to EFV, the 
ICER was most sensitive to time horizon, resistance parameters, and late failure 
probability. conclusions: DTG/ABC/3TC is cost-effective in the management of 
HIV TN patients in France. These results are mainly explained by the lower price of 
DTG/3TC/ABC compared to INIs and PIs, DTG’s superior efficacy and high barrier 
to resistance.
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oBjectives: The development of new highly effective therapies for the treatment 
of hepatitis C virus (HCV), leads to the opportunity to eradicate this infection. In a 
context characterized by a high prevalence of this pathology (i.e. Italy) the investi-
gation of the most efficient therapies to allocate resources to, is crucial. The aim of 
the study was to investigate the cost-effectiveness of Daclatasvir+Sofosbuvir+Rib
avirine therapy, compared with Sofosbuvir+Ribavirine+Peginterferone therapy for 
the treatment of HCV genotype 3 infection in cirrhotic patients within the Italian 
National Health Service. Methods: A published cohort-based Markov simulation 
model (Monarch model) was used to perform lifetime horizon analyses assuming 
the Italian National Health Service point of view. The model simulates the natural 
history of HCV infection and its complications. Patient cohorts were defined based 
on selected clinical studies and eligibility criteria defined by the Italian Medicines 
Agency. The comparator was selected considering EASL guidelines published in 
2015. The costs considered (2015) were direct medical costs, including adverse 
events costs. Utility values were influenced by health status and adverse events 
(anemia, rash, insomnia, headache, fatigue, nausea, diarrhea). Both costs and util-
ity values were discounted using a 3% rate. results: Daclatasvir+Sofosbuvir+ 
Ribavirine for 24 weeks (100% sustained virological response – registry trial) would 
lead to a per capita increase of quality adjusted life years (QALYs) (12.46 vs. 12.10) 
and costs (56,318 € vs. 41,881 € ) compared with Sofosbuvir+Ribavirine+Peginterf- 
erone for 12 weeks (92.06% sustained virological response – PROTON, ELECTRON, 
LONESTAR studies). The incremental cost effectiveness ratio (ICER) is 39,614 € /
QALY. conclusions: Daclatasvir+Sofosbuvir+Ribavirine therapy is likely to be 
cost effective compared with Sofosbuvir+Ribavirine+Peginterferone in genotype 3 
HCV infected cirrhotic patients, leading to an ICER below the 40,000 € /QALY thresh-
old identified by the Italian Association of Health Economics.
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oBjectives: Bedaquiline is a newly introduced agent for the treatment of mul-
tidrug-resistant tuberculosis (MDR-TB) and this study aimed to evaluate the cost 
effectiveness of adding bedaquiline to a standard regimen (SR) to treat patients with 
MDR-TB, including extensively drug resistant tuberculosis (XDR-TB) in comparison 
with standard regimen alone in South Korea. Methods: A cohort based decision 
analytic model developed in a previously published study from the UK was used 
with the following parameters: a 20 year time horizon, and a 5% discount rate for 
cost and effectiveness to evaluate incremental cost-effectiveness ratios (ICER) of 
bedaquiline plus SR and SR alone. Key parameters on clinical data were based on 
the published Phase 2trial of bedaquiline and other parameters for recurrence, 
cured, lost follow-up, surgery, death, cost and health utility were based on Korean 
data if available, otherwise the international literature data were applied. Univariate 
and probabilistic sensitivity analyses were conducted. results: A patient on 
bedaquiline plus SR regimen had 1.20 quality adjusted life years (QALYs) longer 
